Profil
Mark Chao is the founder of Hepatx Corp.
(founded in 2015), Forty Seven, Inc. (founded in 2014), and TenSixteen Bio, Inc. (founded in 2021) where he holds the titles of Senior Vice President & Head-Clinical Development, and Chief Executive Officer respectively.
Dr. Chao is also the founder of Gilead Sciences, Inc...
Dr. Chao's current jobs include being an Advisor at Bioverge Funds Management LLC, a Venture Partner at Foresite Labs LLC, a Scientific Advisory Board Member at IconOVir Bio, Inc., and a Scientific Advisory Board Member at TigaTx, Inc. Dr. Chao's education history includes a graduate degree from Stanford University in 2011, an undergraduate degree from Case Western Reserve University in 2004, and graduate and doctorate degrees from Stanford University School of Medicine in 2011.
Postes actifs de Mark Chao
| Sociétés | Poste | Début |
|---|---|---|
| FORTY SEVEN, INC. | Founder | 01/01/2014 |
Hepatx Corp.
 Hepatx Corp. Packaged SoftwareTechnology Services Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA. | Founder | 01/01/2015 |
TenSixteen Bio, Inc.
 TenSixteen Bio, Inc. BiotechnologyHealth Technology TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation. | Chief Executive Officer | 01/01/2021 |
| Foresite Labs LLC | Private Equity Investor | 01/01/2021 |
IconOVir Bio, Inc.
 IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Consultant / Advisor | 01/12/2021 |
TigaTx, Inc.
 TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Consultant / Advisor | 01/05/2020 |
Bioverge Funds Management LLC
 Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA. | Consultant / Advisor | - |
Anciens postes connus de Mark Chao
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Founder | - |
Formation de Mark Chao
| Stanford University | Graduate Degree |
| Case Western Reserve University | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Bioverge Funds Management LLC
Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA. | Finance |
Hepatx Corp.
Hepatx Corp. Packaged SoftwareTechnology Services Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA. | Technology Services |
| Foresite Labs LLC | |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Health Technology |
TenSixteen Bio, Inc.
TenSixteen Bio, Inc. BiotechnologyHealth Technology TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation. | Health Technology |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Health Technology |
